Search

432 Result(s)
Sort by

Boehringer Ingelheim partners with PetMedix

Boehringer Ingelheim partners with PetMedix

Partnering with PetMedix on Ky9™ platform cutting edge technology as a means to bring innovative new therapies to improve health of animals
emperor-preserved-chmp-positive-opinion

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
New vaccine against Bovine Respiratory Disease

New vaccine against Bovine Respiratory Disease

Boehringer Ingelheim’s Bovalto Respi Intranasal is a new respiratory vaccine for active immunization of cattle against Bovine Respiratory Disease.
empulse-trial-benefit-acute-heart-failure

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
Spotlight on GPP

Spotlight on GPP

Emmanuelle Clerisme-Beaty, former Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.
2019 performance

2019 performance

Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.
Disentangling fibrosis

Disentangling fibrosis

Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
CAROLINA-CARMELINA-Asia-analysis

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
EMPRISE-interim-analysis

EMPRISE-interim-analysis

Interim analysis from EMPRISE real-world study shows decreased risk of hospitalisation for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists
emperor-preserved-kidney-subanalysis

emperor-preserved-kidney-subanalysis

New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
collaboration-LIBD

collaboration-LIBD

Boehringer Ingelheim and The Lieber Institute for Brain Development collaborate on centrally acting COMT inhibitors in neuropsychiatric disorders
CARMELINA-elderly-analysis

CARMELINA-elderly-analysis

CARMELINA® outcome trial subgroup analysis demonstrates long-term cardiovascular and renal safety data in older people with type 2 diabetes